Abstract Nonalcoholic fatty liver disease (NAFLD) is systematically associated with features of metabolic syndrome, a condition carrying a high risk of cardiovascular events. We measured the percent vasodilation of brachial artery in response to ischemia (a test of endothelial function)(FMV) and cardiovascular risk profile in 52 NAFLD cases and 28 age- and gender-matched controls. The 10-year risk of coronary events was calculated according to the Framingham equation and the scores derived from the PROCAM study and NCEP-ATPIII proposals. FMV was 6.33 ± SD 5.93% in NAFLD vs. 12.22 ± 5.05% in controls (P < 0.0001), and higher in pure fatty liver (9.93%) compared with nonalcoholic steatohepatitis (4.94%)(P = 0.010). No differences were observed in flow-independent vasodilation (response to sublingual nitroglycerin). Percent FMV was negatively associated with insulin resistance (homeostasis model assessment) in the whole population (r = -0.243; P = 0.030). In logistic regression analysis, NAFLD was associated with a percent FMV in the lower tertile (odds ratio, 6.7; 95% confidence interval, 1.26-36.1), after adjustment for age, gender, BMI and insulin resistance. Among NAFLD patients, low FMV was associated with nonalcoholic steatohepatitis (adjusted-odds ratio, 6.8; 1.2-40.2). The 10-year probability of cardiovascular events was moderately increased in NAFLD, and particularly in nonalcoholic steatohepatitis. Our study provides evidence of endothelial dysfunction and increased risk of cardiovascular events in NAFLD. The risk of advanced liver disease is well-recognized in NAFLD patients, but the large majority of cases might probably experience cardiovascular disease in the long-term, indirectly limiting the burden of liver failure.

Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease / N. Villanova; S. Moscatiello; S. Ramilli; E. Bugianesi; D. Magalotti; E. Vanni; M. Zoli; G. Marchesini Reggiani. - In: HEPATOLOGY. - ISSN 0270-9139. - STAMPA. - 42:(2005), pp. 473-480. [10.1002/hep.20781]

Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease

MOSCATIELLO, SIMONA;ZOLI, MARCO;MARCHESINI REGGIANI, GIULIO
2005

Abstract

Abstract Nonalcoholic fatty liver disease (NAFLD) is systematically associated with features of metabolic syndrome, a condition carrying a high risk of cardiovascular events. We measured the percent vasodilation of brachial artery in response to ischemia (a test of endothelial function)(FMV) and cardiovascular risk profile in 52 NAFLD cases and 28 age- and gender-matched controls. The 10-year risk of coronary events was calculated according to the Framingham equation and the scores derived from the PROCAM study and NCEP-ATPIII proposals. FMV was 6.33 ± SD 5.93% in NAFLD vs. 12.22 ± 5.05% in controls (P < 0.0001), and higher in pure fatty liver (9.93%) compared with nonalcoholic steatohepatitis (4.94%)(P = 0.010). No differences were observed in flow-independent vasodilation (response to sublingual nitroglycerin). Percent FMV was negatively associated with insulin resistance (homeostasis model assessment) in the whole population (r = -0.243; P = 0.030). In logistic regression analysis, NAFLD was associated with a percent FMV in the lower tertile (odds ratio, 6.7; 95% confidence interval, 1.26-36.1), after adjustment for age, gender, BMI and insulin resistance. Among NAFLD patients, low FMV was associated with nonalcoholic steatohepatitis (adjusted-odds ratio, 6.8; 1.2-40.2). The 10-year probability of cardiovascular events was moderately increased in NAFLD, and particularly in nonalcoholic steatohepatitis. Our study provides evidence of endothelial dysfunction and increased risk of cardiovascular events in NAFLD. The risk of advanced liver disease is well-recognized in NAFLD patients, but the large majority of cases might probably experience cardiovascular disease in the long-term, indirectly limiting the burden of liver failure.
2005
Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease / N. Villanova; S. Moscatiello; S. Ramilli; E. Bugianesi; D. Magalotti; E. Vanni; M. Zoli; G. Marchesini Reggiani. - In: HEPATOLOGY. - ISSN 0270-9139. - STAMPA. - 42:(2005), pp. 473-480. [10.1002/hep.20781]
N. Villanova; S. Moscatiello; S. Ramilli; E. Bugianesi; D. Magalotti; E. Vanni; M. Zoli; G. Marchesini Reggiani
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/4639
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 532
  • ???jsp.display-item.citation.isi??? 482
social impact